QuidelOrtho (QDEL) Q1 2026 Earnings Transcript

QuidelOrtho reported Q1 revenue of $620 million, but respiratory revenue fell sharply to $68 million as influenza-like illness visits declined about 30% year over year, driving adjusted gross margin down 630 bps to 44% and adjusted EBITDA to $109 million. Management cut full-year revenue guidance to $2.0 billion-$2.75 billion and cited a roughly $30 million China headwind from pending IVD pricing guidelines, while also lowering free cash flow expectations to $100 million-$120 million. Offsetting factors include the Lex Diagnostics acquisition, new product launches, and a reaffirmed mid-20s EBITDA margin improvement plan over time.

Analysis

The market is likely underestimating how much of the 2026 reset is a timing issue versus a structural one. The near-term guide cut is being driven by two temporary demand air pockets — respiratory normalization and China distributor destocking ahead of pricing changes — but the more important second-order effect is margin mix: every dollar of lower respiratory and China volume hurts EBITDA disproportionately because those categories were subsidizing fixed-cost absorption. That means Q2 and likely Q3 can look mechanically worse on operating leverage even if underlying franchise health is stable.

The bigger competitive implication is that QDEL is effectively signaling it will defend China economics rather than exit, which should pressure smaller diagnostics peers to choose between volume and price. If the company really can hold share through pricing resets, the eventual loser is likely not QDEL but lower-scale competitors and distributors with weaker service density. Conversely, the Lex platform creates a new switching wedge in point-of-care, but the ramp is capacity-limited, so the first 6-9 months may be more of a credibility test than a revenue event; that limits upside to 2026 but sets up a cleaner 2027 inflection if execution holds.

The contrarian setup is that the stock may have already priced in the bad respiratory print, but not the sequencing of cash flow. Inventory build plus leverage above 4x means management has less room for a second disappointment, so any delay in China stabilization or a weak 2H respiratory rebound could force another de-rate. On the other hand, if China normalizes faster than expected and Q2 confirms year-over-year growth, the path to mid-20s EBITDA margins becomes much more believable because the cost actions are already in flight; the asymmetry is better on a 6-12 month horizon than a 1-2 month horizon.

Key Decisions for Investors

• Avoid chasing QDEL on the print; wait for either a better entry after Q2 or evidence that China distributor inventory has cleared. Risk/reward is poor in the next 4-8 weeks because the stock can be punished again on any guide skepticism.
• For event-driven longs, consider a small QDEL long dated 6-9 months out only on confirmation of sequential revenue stabilization in Q2 and no further China guide cuts. Upside is a re-rate toward execution credibility; downside is another multiple compression if cash flow or leverage worsens.
• Pair trade: long larger-cap diagnostics with diversified revenue mix against short QDEL if you want to express relative weakness in respiratory/China cyclicality. The thesis is that QDEL has the most operating leverage to second-half disappointment.
• Use GRFS as a secondary relative short/underweight where applicable: the end of the joint business relationship is a cleaner way to play revenue loss without paying for QDEL’s optionality, but the better expression remains QDEL vs diversified peers.
• For options, consider selling near-term QDEL puts only if you are willing to own the name at a lower basis; implied volatility should remain elevated into the next respiratory data point and China policy updates, making premium capture attractive if support holds.